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FSGSSince the beginning of the 20th century human life expectancy has doubled to more than 80 years, and growth
and aging of the world population now represent major challenges for healthcare providers, political decision
makers, and societies. Cellular senescence is associatedwith a general, pro-inﬂammatory state, which represents
the common denominator between aging and chronic diseases and their progression. Approaches to interfere
with these changes and to allow healthy aging involvemodulation of the cellular activity of modiﬁablemolecular
mediators (MMMs), such as signaling molecules and growth factors. ET-1 – the biologically predominant mem-
ber of the endothelin peptide family – is an endothelial cell-derivedpeptidewith awide variety of developmental
and physiological functions, which include embryogenesis, nociception, and natriuresis. In addition, ET-1 is a
cytokine-like, multifunctional peptide with pro-inﬂammatory, mitogenic, and vasoconstrictor properties. If pro-
duced in excess amounts ET-1 promotes disease—mainly via activation of its ETA receptor. Because of its multiple
disease-promoting functions ET-1 represents an ideal target MMM. Preclinical studies targeting either activity or
production of ET-1 – utilizing ERAs, ARBs, or ACEIs, respectively – have demonstrated that partial regression of
aging-associated changes in vasculature and kidney is possible. In this article I will review the molecular regulation
of ET-1 and its role in thephysiologyof vascular homeostasis, aging, and cellular senescence. The clinical implications
of activators of ET-1 overproduction, modalities for delaying or reversing aging-related cellular changes, as well as
interventions to promote healthy aging and early disease prevention – particularly physical activity – are discussed.
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Already in the 17th century, physician Thomas Sydenham M.D.
(1624–1689), known as the “English Hippocrates” (Bendiner, 1986),
recognized that vascular health and aging are interdependent and
inversely related. This is reﬂected by Sydenham's above quote
(O'Rourke and Hashimoto, 2007), which has also been attributed to
Canadian physician Sir William Osler, M.D. (1849–1919), the father of
modern medicine (Barton, 2013d; Sawabe, 2010). The direct
relationship between aging and vascular health is clinically apparent
in progeria syndromes: These patients show accelerated aging,
abnormal endothelium-dependent vascular function, accelerated
atherogenesis, and die within the ﬁrst three decades of life mostly from
clinical complications of vascular disease such as myocardial infarction
and stroke (Capell et al., 2007; Merideth et al., 2008; Nabel, 2012).
Aging populations: challenge for the future
Today, age-related morbidity – which primarily involves sequel-
ae of vascular disease (Barton, 2005a) – continues to pose great
challenges to health care providers, health insurances, political deci-
sion makers, and societies (Barton, 2012). Indeed, life expectancy in
humans has doubled since the beginning of the 20th century and in
most developed countries now exceeds 80 years in both men and
women (Barton, 2005b; Barton and Meyer, 2009; Gerland et al,
2014). In addition, as a consequence of a changes in birth rates and
increased longevity, the world population is expected to continue
to grow over the next decades — particularly among the elderly
(Barton, 2005b; U.S. Census Bureau, 2002; Gerland et al, 2014)(Fig. 1). This will result in an overall shift of the world's age proﬁle
with the according increase in the oldest-old and their associated
multimorbidity and frailty (Dong et al., 2013; Lofﬂer et al., 2012; Gerland
et al, 2014). When we are taking care of patients with chronic diseases,
we areoften facing that advanced age is accompaniedwithmultimorbidity
and greater susceptibility to medical complications. Thus, advanced age
becomes an important determinant of mortality in critically ill patients
(Barton, 2005a). The increased age-related risk may be partly related to
changes in immunity and the overall immune defense in the elderly
which have been linked to the increased susceptibility for disease (includ-
ing an increased incidence of cancer) and infection (Franceschi et al., 2000;
Gruver et al., 2007; Thoman and Weigle, 1989) (Boraschi et al., 2010).
Immunosenescence has been implicated in the clinical course of viral or
bacterial infections in the elderly who more often become critically ill
than do middle-aged adults (Aw et al., 2007; Girard and Ely, 2007).Aging and prevalence of chronic, non-communicable disease
In the industrialized world, a number of certain chronic, non-
communicable diseases show a much higher prevalence in the elderly
(Mokdad et al., 2004). These diseases include vascular disease, stroke,
myocardial infarction, heart failure, diabetes, obesity, and cancer
(Fig. 2) and dementia. The likelihood to develop or die from these
diseases increases as we age (Harman, 1991, 1996; Mokdad et al.,
2004). The aging process sets the stage for some of these diseases to
develop. Moreover, endocrine changes related to physiological aging
such asmenopause result in conditions that resemble disease-like states
(Barton, 2013b,c; Barton and Meyer, 2009): for instance, women after
menopause become prone to develop obesity, insulin resistance, and
diabetes, as well as stiffening of the arterial vascular bed and develop-
ment of arterial hypertension (Barton and Meyer, 2009). All these fac-
tors increasing the risk of vascular disease (Virdis et al., 2009).
Importantly, the number of postmenopausal women is expected to in-
crease to approximately to 1 billion worldwide by the year 2050
(Barton and Meyer, 2009) (Fig. 1), indicating the need for health and
disease prevention also in this group (Lobo et al., 2014).
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Fig. 1. Projected development of the world population until the year 2050 divided by sex, as calculated by the U.S. Census Bureau, International Programs Center, International Data Base
based on year 2002 data. Theworld population is expected to grow by one third from 6.2 billion in 2002 tomore than 9 billion in 2050 and to 12.7 billion by the year 2100 (Gerland et al.,
2014). Importantly, the number of individuals aged 50 years and older – particularly in women –will increase by factor 2 to 5, resulting in an overall population proﬁle shift towards an
“aged” population. Calculations predict close to 6% of theworld population (half a billionmen andwomen) to be 80 years and olderwithin thenext 35 years. Adapted from theU.S. Census
Bureau, International Programs Center, International Data Base (U.S. Census Buro, 2002).
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Inﬂammation: common denominator of progression in aging and disease
Aging is a physiological process that also represents the most
frequent cause of death after age 28 and can be viewed as “the accumu-
lation of [physiological] changes for the sequential alterations that
accompany advancing age and the associated progressive increases in
the chance of disease and death” (Harman, 1991, 1992). Of note, most$FWLYDWLRQRI(QGRWKHOLQLQ$JLQJ$VVRFLDWHG'LVHDVHV
Fig. 2. Human diseases and disease risk factors with a high incidence and prevalence
among the aging population. These diseases include arterial hypertension, atherosclerosis
(coronary artery disease/myocardial infarction, cerebrovascular disease/stroke, aortic
aneurysms), heart failure, obesity, insulin resistance, diabetes, chronic renal disease/
impairment of renal function, and cancer. Of note, each of these conditions or diseases
has been shown to be associated with an activation of the endothelin system, and for
most of these conditions treatment with an ERA (mostly in experimental studies) has
been shown to improve either clinical parameters, disease severity, or to reduce progres-
sion. For some of these conditions, ERA treatmentwas even associatedwith partial regres-
sion of disease.recent data indicate that senescence already plays a role in embryogen-
esis, the ﬁrst step of life, where aging mechanisms including apoptosis
regulate embryonic growth and patterning (Campisi, 2014; Muñoz-
Espín et al., 2013; Storer et al., 2013). There are high similarities be-
tween the cellular changes related to aging and those found in some
of the most common chronic non-communicable and mostly multifac-
torial diseases. Similarities between disease and aging can be found in
hypertension, diabetes, obesity, atherosclerosis, or glomerulosclerosis,
at the molecular, cellular, and also the functional/organ levels (Barton,
2013d). It is now well established that cellular senescence is associated
with activation of pro-inﬂammatory pathways (Franceschi et al., 2000;
Howcroft et al., 2013),which represents the unifying, “commondenom-
inator” between aging and progression of chronic disease. Indeed, aging
is associated with speciﬁc changes in innate and adaptive immunity,
promoting a pro-inﬂammatory milieu (Bruunsgaard et al., 2003;
Chung et al., 2009; Michaud et al., 2013). Age-dependent inﬂammatory
activation (Franceschi et al., 2000; Howcroft et al., 2013) likely also at
least in part underlies the cellular changes seen with aging, such as vas-
cular hypertrophy and myocardial injury (Lakatta, 2003; Olivetti et al.,
1991) or glomerulosclerosis in the course of renal aging (Baylis and
Corman, 1998; Baylis and Schmidt, 1996; Ortmann et al., 2004; Yang
and Fogo, 2010). Because the pro-inﬂammatory (and thus growth-
promoting) cellular changes cellular that characterize aging closely re-
semble those present in arterial hypertension, diabetes, or chronic kid-
ney disease (Barton, 2005a; Lakatta, 1987; Lakatta et al., 1987), aging
further accelerates these disease processes.Aging results in cell and organ injury
Aging affects organs, cells, and their physiological functions (Folkow
and Svanborg, 1993). At the level of the endothelium, aging is associated
with shortening of telomeres, apoptosis, dysmorphic, enlarged and
dysfunctional endothelial cells, augmented endothelium-dependent
vasoconstriction, decreased NO bioactivity, and reduced endothelium-
100 M. Barton / Life Sciences 118 (2014) 97–109dependent angiogenesis (reviewed in Barton, 2005a, 2010; El Assar
et al., 2012; Hayashi et al., 2008). In vascular smooth muscle cells,
aging promotes cell growth, vascular hypertrophy and stiffening of the
arterial wall (Cockcroft and Mancia, 2012; Folkow and Svanborg,
1993; McEniery et al., 2005). As a consequence, arterial blood and
pulse pressure increase in aging humans and rodents (Barton, 2005a,
2010; El Assar et al., 2012). In the kidney, physiological aging is associ-
ated with a decline in glomerular ﬁltration rate and spontaneous devel-
opment of focal-segmental glomerulosclerosis (Ortmann et al., 2004)
and tubulo-interstitial injury (Tonelli and Riella, 2014; Yang and Fogo,
2010). Many of the cellular and structural abnormalities in the aging
kidney resemble those observed in patientswith renal disease due to di-
abetes, obesity, or arterial hypertension (Bolignano et al., 2014). It thus
appears acceptable to compare pathological changes due to arterial hy-
pertension or obesity with premature aging (Bhattacharya et al., 2008;
Taddei et al., 1997) or accelerated vascular senescence (Brodsky et al.,
2004; Wang et al., 2009). As discussed above, vascular inﬂammation
has been identiﬁed in arterial hypertension (Guzik et al., 2007;
Harrison et al., 2012; Schiffrin, 2014) as well as in aging (Bural et al.,
2013; Ferrucci et al., 2005; Franceschi et al., 2000; Wang et al., 2007).
Preventive measures or therapeutic interventions should thus be
targeted towards reducing inﬂammation (Barton, 2013d). This is partic-
ularly important in view of the high number of aged patients diagnosed
with obesity and diabetes, which show the prevalence among all age
groups (Bramlage et al., 2004).
Vascular endothelial cells: regulators of cellular homeostasis
Foreseeing endothelial cell biology in the 1950s
To help understand how aging affects endothelial mediators and their
activity I will give a short overview of themain factors involved. I will also
put them in the historical context of their discovery. The recognition of
the role of endothelial cells as regulators of cell homeostasis goes back
only 60 years. Anatomist and pathologist Rudolf Altschul, M.D. (1901–
1963), graduated from the German University in Prague, Bohemia, in
1925 and emigrated to Saskatchewan, Canada (Fedoroff, 1991), where
in the early 1950s he developed a theory that he published in the ﬁrst
book solely dedicated to the vascular endothelium:
“The largest number of natural deaths from a single cause in North
America … is ascribed to cardiovascular diseases. Because the great
majority of [fatal] heart disease is caused by coronary [artery] thrombo-
sis, we may as well cancel the ﬁrst word in ‘cardio-vascular’ and
conclude that … most people succumb to a ‘vascular’ disease. Blood
vessels… are primarily endothelial [lined] tubes … and therefore, …
the endothelium has a great importance to our life and its failure will
cause the death of many of us” (Altschul, 1954).
In his book, Altschul continues:
“While working on the problem of arteriosclerosis I have realized not
only how little I know about the endothelium — but also how much I
ought to know for the proper understanding of arteriosclerosis”
(Altschul, 1954).
Altschul probably was not aware that he had just come up with a
visionary hypothesis, and that only a few decades later his hypothesis
would be conﬁrmed. Robert Furchgott, Ph.D. – one of the central ﬁgures
in vascular and endothelial cell biology (Nilius et al., 2010) – actually
began his research at the time of Altschul's writings (Furchgott, 1955,
1995).
EDRF, EDCF, ADRF, ADCF, and prostaglandins
In the late 1960s, Vane, Moncada and colleagues' work led to the
discovery of the prostaglandins released from endothelial cells and thecyclooxygenase enzymes (Barton, 2011; Moncada et al., 1976;
Moncada and Vane, 1979): At the same time Ross and Glomset put
forward their response-to-injury theory of atherosclerosis, identifying
the endothelial cells' protective role in preventing proliferation of the
underlying vascular smooth muscle (Hanke et al., 2001; Ross and
Glomset, 1973). On May 5, 1978, Furchgott accidentally discovered
endothelium-dependent dilatation, mediated by a then unknown
EDRF (endothelium-derived relaxing factor) (Furchgott, 1993;
Furchgott and Zawadzki, 1980; Furchgott, 1995). In the early 1980s,
de Mey and Vanhoutte reported endothelium-dependent vasoconstric-
tion via an EDCF (endothelium-dependent contracting factor) (De Mey
and Vanhoutte, 1982), subsequently found to be cyclooxygenase-
derived prostanoids (Barton, 2011). Shortly thereafter, EDRF was iden-
tiﬁed as nitric oxide (NO) (Furchgott, 1993; Ignarro et al., 1987;
Palmer et al., 1987) — a discovery which was awarded the Nobel Prize
in Physiology or Medicine in 1998 (Raju, 2000). In 1988, the molecular
structure of a peptidergic vasoconstrictor was identiﬁed (Yanagisawa
et al., 1988). However, control of vascular tone turned out to be far
more complex and not solely controlled by signals originating from en-
dothelial cells: It took 20 more years until Löhn et al. discovered
adipose-derived relaxing factor (ADRF) (Löhn et al., 2002), and another
10 years before Meyer et al. identiﬁed adipose-derived contracting fac-
tor (ADCF) (Meyer et al., 2013),which – just like EDCF – exerts vasocon-
striction through cyclooxygenase-derived vasoconstrictor prostanoids.
Whether and how aging affects ADRF and ADCF has not yet been
studied.
Endothelium-derived endothelin: a vasoconstrictor and more
The discovery of the endothelium-derived vasoconstrictor
endothelin resulted from the search of the identiﬁcation of the chemical
nature of Furchgott's EDRF, which was published only in 1987
(Furchgott, 1993; Ignarro et al., 1987; Palmer et al., 1987). Researchers
had been unsuccessful to reproduce any vasodilator activity in endothe-
lial cell supernatants after prolonged culture but instead observed very
potent vasoconstrictor responses (Barton and Pollock, 2012). This lead
to another accidental discovery in endothelial cell biology, that of a
peptidergic vasoconstrictor (Hickey et al., 1985; O'Brien et al., 1987;
Rubanyi, 2011). The molecular identity of this vasoconstrictor peptide
was deciphered by Yanagisawa, Goto, Masaki and colleagues in 1988
and designated endothelin-1 (ET-1) due to its endothelial cell origin
(Yanagisawa et al., 1988). Although initially identiﬁed as the most
potent vasoconstrictor known to date, it became soon clear that ET-1
is not simply a vasoconstrictor peptide but rather a multifunctional,
cytokine-like molecule (Krämer et al., 1992) with numerous activities
that affect all levels of cell function (reviewed in Barton and Kiowski,
2001). These functions include embryonic development, salt–water
balance, nociception, and neuronal functions, among others
(Kedzierski and Yanagisawa, 2001; Kohan et al., 2011b; Schneider
et al., 2007). Particularly important are the cellular properties of the
ET-1 peptide that are related to inﬂammation and proliferation
(Fig. 3), cellular events associated with the onset and perpetuation of
chronic diseases. Research in the endothelin ﬁeld, which Salvador
Moncada in an early editorial comment referred to as “the endothelin
explosion” (Whittle and Moncada, 1990), has resulted in about 1000
scientiﬁc articles annually since its discovery in 1988 (Barton and
Pollock, 2012).
Aging and endothelin: brothers in arms sharing similar disease
mechanisms
Aging and disease: causes of endothelial cell disbalance
When we look at the function of healthy endothelial cells and
the substances they produce, we realize that the substances released
are “agonists” and “antagonists” with regard to their functions,
3UR,QIODPPDWRU\DQG*URZWK3URPRWLQJ$FWLYLWLHVRI(7
Fig. 3. Schematic representation of interactions between cells, the arterial blood vesselwall, and the blood inwhich ET-1 peptide is involved. ET-1 contributes to inﬂammation, stimulation
of cell growth, regulation of vascular tone and homeostasis or circulating cells, including platelets andwhite blood cells. See text for details. Abbreviations: Ang II, angiotensin II; ANP, atrial
natriuretic peptide; ECE, endothelin converting enzyme; ET-1, endothelin-1; ETA, endothelin ETA receptor; ETB, endothelin ETB receptor; NO, nitric oxide; NOS, nitric oxide synthase; •O2−,
superoxide anion; IL-1, interleukin 1; IL-6, interleukin 6, IL-8, interleukin 8; TGFβ-1, transforming growth factor β-1; bFGF-2, basic ﬁbroblast growth factor-2; NADPHox, NADPH oxidase,
ONOO−, peroxynitrite; PAI-1 plasminogen activator inhibitor-1; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; (+), stimulation, (−), inhibition.
Reproduced with permission from Barton M, Luscher T. Endothelin antagonists for hypertension and renal disease. Curr Opin in Nephrol Hypertens 1999; 8: 549–556.
101M. Barton / Life Sciences 118 (2014) 97–109representing disease promoters and inhibitors, respectively (Barton,
2013d) (Fig. 4). Endothelial cell-derived disease promoters include
vasoconstrictor substances, growth promoters, pro-coagulatory
substances, and pro-inﬂammatory substances/cytokines (reviewed
in Barton, 2013d; Luscher and Barton, 1997). Of note, ET-1, like an-
giotensin II (Dzau, 1986), is one of the few endogenous peptides
that qualify as a multifunctional, cytokine-like peptide with activity
in these areas, promoting vasoconstriction, cell proliferation, coagu-
lation, and inﬂammation (reviewed in Barton and Yanagisawa,
2008). Similar activities can be attributed to reactive oxygen species
(ROS), which interestingly are stimulated by both angiotensin II and
ET-1 (Barton and Yanagisawa, 2008) and play an important role in
disease processes and aging (Brandes et al., 2010). The disease-
propagating of endothelial cells, however, become apparent only if
these mediators are produced or active at excess concentrations. These
are then counter-balanced by vasodilators, growth inhibitors, anti-
coagulatory and anti-inﬂammatory substances, among which nitric
oxide (NO) represents the perhaps most important example (Barton,
2013d) (Fig. 4). In youth and under healthy conditions, the release of
these constitutively formed, endothelium-derived substances is in bal-
ance. However, when we become ill, obese, or whenwe age, this balance
is tipped towards the “disease-promoting” properties of endothelial cells
(Barton, 2010; El Assar et al., 2012) (Fig. 4). These changes also include in-
creased expression, release, and activity of ET-1 (Fig. 3). Thus, aging and
themost prevalent chronic diseases (arterial hypertension, diabetes, obe-
sity, atherosclerosis, and chronic renal disease) are associated with the
comparable changes in endothelial cell pathways and with inﬂammatory
activation (Csiszar et al., 2003, 2004), both favoring disease development
and progression (Barton, 2013d).Disease conditions promote endothelin overproduction
Overproduction of ET-1 is present in patients and experimental
models of arterial hypertension, chronic renal disease, and diabetes
(Barton et al., 2012; Kohan and Barton, 2014) (Fig. 2). In order to under-
stand the mechanisms through which ET-1 promotes disease, we need
to ﬁrst look at how ET-1 synthesis is regulated. As it turns out, almost
all chronic, progressive diseases also show an increase in the production
and/or release of ET-1 (Barton, 2010; Campia et al., 2014-in this issue;
Matsumoto et al., 2014-in this issue) (Fig. 5). Notably, cellular stimuli
and mediators activated in chronic diseases turn out to be mostly iden-
tical to those that regulate endothelin synthesis (Barton, 2010). In the
vascular system, ET-1 is produced predominantly by vascular endothe-
lial cells and vascular smooth muscle cells, and by resident white blood
cells (Ehrenreich et al., 1990; Sessa et al., 1991a, 1991b). The ET-1
peptide is released in response to stimuli such angiotensin II, thrombin,
PAI-1, thrombin, decreased pH and also by autocrine stimulation
through ET-1 (reviewed in Barton and Kiowski, 2001) (Fig. 3). Produc-
tion of ET-1 is inhibited by ANP, estrogen, prostacyclin, and nitric
oxide (NO). Stimulation of endothelial ETB receptors stimulates release
of nitric oxide and adrenomedullin as well as vasorelaxation (Fig. 3); by
contrast, activation of ETA receptors induces contraction, cell prolifera-
tion, and migration (Miyagawa and Emoto, 2014). In addition to being
a growth factor itself, ET-1 stimulates the production and potentiates
the action of several growth factors, increases DNA and protein synthe-
sis, and promotes cell cycle progression (Fig. 3), all of which stimulate
growth (Barton and Kiowski, 2001). ET-1 also stimulates platelet
aggregation via the ETA receptor (Touyz et al., 1995), promoting
a prothrombotic state. In addition, ET-1 itself has direct, pro-
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Fig. 4. Endothelium-derived substances are crucially involved in protection from and progression of disease. Shown are effects of physiological (aging) and pathological conditions
(disease) on the shift in balance of release and/or activity of endothelium-derived substances. Shown at the bottom of the ﬁgure are electron microscopy images of three endothelial
cells with their nuclei. Intact endothelial cell function is determined by a ﬁnely tuned balance between disease-propagating (here designated as disease “agonists”) and protective
substances (here designated as disease “antagonists”). It is important to keep in mind that all these substances ensure normal endothelial cell functions under physiological conditions.
Only when produced in excessive amounts in conditions such as disease and aging, vasoconstrictors (including ET-1 and superoxide anion), growth factors, pro-coagulatory substances,
cytokines, and pro-inﬂammatory mediators become disease-propagating substances. By contrast, vascular health is critically dependent on the sufﬁcient, constitutive endothelial release
of vasodilators (the main one being nitric oxide, NO), growth inhibitors, inhibitors of thrombosis, and synthesis of anti-inﬂammatory substances. Both under physiological (aging) and
pathological conditions (i.e. atherosclerosis, chronic renal disease), the balance of endothelium-derived substances shifts towards overproduction of “disease-agonists”, whereas produc-
tion and/or activity of vasoprotective mediators are reduced, favoring disease development and progression.
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antagonists (ERAs) have been shown to inhibit inﬂammation (Barton
et al., 2010; Lattmann et al., 2005a; Sasser et al., 2007). The indirect
and direct effects of ET-1 on inﬂammation are likely to be functionally
important for the aging process.ET-1
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Fig. 5. Summarized representation of cellular and biological factors, physiological condi-
tions, and diseases that have been implicated both in disease progression and activation
of the endothelin system. These include reactive oxygen species (ROS), aldosterone, angio-
tensin II, cholesterol, insulin/elevated levels in insulin resistance, glucose/hyperglycemia,
obesity, arterial hypertension, inﬂammation, as well as physiological conditions such as
aging and menopause (estrogen deﬁciency). Figure modiﬁed from Barton M. Reversal of
proteinuric renal disease and the emerging role of endothelin. Nature Clin Pract Nephrol
2008; 4: 490–501.The aging process: activator of the endothelin system
Aging changes plasma levels and contraction to endothelin
Excessive production of ET-1 is present in patients and experimental
models of aging (Donato et al., 2009; Goettsch et al., 2001). Preclinical
studies have demonstrated causal relationships between ET-1 and
age-dependent development of disease (Donato et al., 2005; Ortmann
et al., 2004). However, it is not clear how much of the increased local
ET-1 in human aging (Donato et al., 2009) is secondary to underlying
disease processes or inﬂammation, or whether local ET-1 concentration
is in fact causal for the disease progression. Aging as a disease-prone
physiological process has been in the focus of endothelin researchers
from the beginning. As early as 1991, Mikawa and associates reported
the surprising ﬁnding that circulating levels of ET-1 are very high in
early infancy and decrease during childhood (Yoshibayashi et al.,
1991). We began studying the interactions between aging and the
endothelin system in the mid-1990s. Very advanced aging in rodents
slightly increases circulating levels of ET-1, as well as functional activity
of endothelin converting enzyme (Barton et al., 1997a). Contractions to
ET-1 weremeasured in different vascular beds and found to be reduced
only in those arteries where endothelium-dependent relaxation was
also reduced (Barton et al., 1997a). Studying younger animals and
usingdifferent strains and vascular beds, other investigators also report-
ed increased contractions ET-1 in aging rat arteries (Donato et al., 2005;
Korzick et al., 2005). Our recent data obtained in mice indicates that
advanced aging abrogates contractions in conduit arteries. The data
further indicate that contraction to ET-1 in aged mice is largely mediat-
ed by cyclooxygenase products (Meyer et al., 2014-in this issue-b) and
independent of NADPH-oxidase dependent ROS formation (Meyer
et al., 2013). This is in line with earlier studies in younger mice
(Widmer et al., 2006) (Kretz et al., 2006).
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We then started measuring local concentrations of endothelins
in vascular tissues utilizing a method we developed together
with Dr. Sidney Shaw, a biochemist at the University of Bern,
who established a novel radio-immuno assay/HPLC detection of
endothelin peptides from very small samples. This assay was essen-
tial to reliably quantify endothelin levels in small tissue samples. An-
alyzing vascular ET-1 peptide concentrations, we found that aging
increases vascular ET-1 levels, and that the degree of increase de-
pends on the topography of the vascular bed studied (Goettsch
et al., 2001). The ﬁnding that aging increases ET-1 was conﬁrmed
by Flavahan and colleagues (Goel et al., 2010), extending them by
demonstrating an increase in thrombin stimulated, exocytosis-
mediated release from endothelial cell storage vesicles, the main
stores of pre-formed, endothelial ET-1 in the vascular wall
(Harrison et al., 1995). The ﬁndings in the blood vessels prompted
us to also look at the kidney, where we likewise found that aging in-
creases steady-state gene expression of prepro-endothelin-1 mRNA
in cortex andmedulla of the kidney, while renal ETA and ETB receptor
expression and distribution remaining unaffected (Lattmann et al.,
2005b). The increase in renal ET-1 was inversely related to tissue
levels of stable NO metabolites NO2/NO3 (Barton et al., 2000b). To
our surprise, ET-3 – the endogenous “antagonist” of ET-1 (Barton
and Yanagisawa, 2008) – also increased with aging in both renal me-
dulla and cortex (Lattmann et al., 2005b), possibly providing an en-
dogenous protective mechanism against the overproduction of ET-
1. An involvement of ET-1 in the age-dependent impairment of
endothelium-dependent vasomotion is suggested in from work by
Donato and colleagues who demonstrated that ERA treatment re-
stores the attenuated relaxation in carotid arteries from old mice
(Donato et al., 2009). Work from Lerman's group using a model of
Alzheimer's disease and aging displaying abnormal vascular function
supports this notion, as an ERA normalized function also in this
model (Elesber et al., 2006).A role for endothelin in human aging
Increases in ET-1 have been also observed in aged humans, both
with regard to circulating levels (Maeda et al., 2003; Donato et al.,
2009) as well as expression of ET-1 in the human brachial artery
(Donato et al., 2009). There is also indirect evidence indicating that
endogenous ET-1 increases with age in humans: Endothelin receptor
antagonists (ERAs) cause greater increases in lower limb blood ﬂow in
healthy sedentary old subjects than in young subjects, which would
be consistent with the notion that increased local ET-1 contributes to
the greater vasoconstrictor tone in peripheral arteries of aged humans
(Thijssen et al., 2007). Like in studies in aged rats (Barton et al.,
1997a) andmice (Meyer et al., 2013, 2014-in this issue-b) vasoconstric-
tion to ET-1 is blunted in older sedentary subjects (Van Guilder et al.,
2007), possibly due to down-regulation or functional impairment of
endothelin receptor signaling due to increased local ET-1 concentra-
tions. As with studies in the peripheral circulation, ERAs cause increases
in resting forearm blood ﬂow only in old sedentary subjects, but not in
young healthy volunteers (Van Guilder et al., 2007). Moreover,
endothelium-dependent vasodilator responses in the forearm of older
subjects are inversely correlated with the expression of ET-1 in endo-
thelial cells (Donato et al., 2009), again compatible with an essential
role of ET-1 regulating vasomotor tone with aging. Taken together,
there is compelling evidence from experimental and human studies
suggesting that aging – as a physiological, “endogenous stimulus” – ac-
tivates the tissue endothelin system, and that its excessive production
likely contributes to its role as a modiﬁer of cell and organ function
and likely represents an important endogenous propagator of diseases
which increase with age.Interfering with endothelin: pharmacological approaches and
endothelial therapy
Aging is not inexorable: role of modiﬁable molecular mediators (MMMs)
Only recently, the reversibility of certain aspects of aginghas become
increasingly appreciated (Najjar et al., 2005; Newgard and Sharpless,
2013). Studies published over the past decade provide compelling
evidence that aging-associated cellular changes may not be all inexora-
ble, but that aging– similar to arterial hypertension and obesity – can be
considered a modiﬁable risk factor (Beauséjour et al., 2003; Mercken et
al., 2013a;Mercken et al., 2013b).With this article I am thus introducing
the term “modiﬁable molecular mediator” (MMM) to indicate those bi-
ological factors thatwe can target in order to slow down or even reverse
disease or physiological conditions such as aging. MMMs are not neces-
sarily identical with, but may also represent potential drug targets.
MMMs particularly include those peptides exerting their activities
through G protein-coupled receptors (GPCRs) and that are centrally in-
volved said processes propagating inﬂammation and cell proliferation.
ET-1 and angiotensin II represent examples of an MMM, and can be
targeted either by drugs or also by other interventions that will be
discussed further below.
Addressing the future of aging research in biomedicine ten years
ago (Barton, 2005b) I asked: “Cardiovascular aging: the point of no
return?” It turns out that changes due to aging are not inexorable
but in fact accessible to numerous (therapeutic) interventions (Ma
et al., 2000; Newgard and Sharpless, 2013; Adamczak et al., 2004,
2003; Benigni et al., 2009; Dorshkind and Swain, 2009; Laufs et al.,
2004; Montecino-Rodriguez et al., 2013; Ortmann et al., 2004;
Werner et al., 2009, 2008). Blocking the activity of ET-1 represents
one of them.Endothelin and reversibility of aging-associated organ injury
Evidence that age-related organ injury is endothelin-dependent
and in part reversible was generated in 2004 (Ortmann et al., 2004;
Placier et al., 2006). We initially observed marked local increases of
ET-1 in aged glomeruli (Goettsch et al., 2001). In view of the pro-
ﬁbrotic, pro-inﬂammatory activity of ET-1 (Rodriguez-Pascual
et al., 2014-in this issue) (Fig. 3) and the nephroprotective effects
of ERAs in hypertension (reviewed in Barton and Luscher, 1999),
we postulated that the age-dependent increase of ET-1 might in
part underlie the spontaneous development of age-dependent
glomerulosclerosis, and that blocking ETA receptors might interfere
with this process. Unexpectedly, short-term ERA treatment of
established glomerulosclerosis for only a few weeks resulted in par-
tial regression and normalization of glomerular capillary wall thick-
ness (Fig. 6, Ortmann et al., 2004). Treatment also resulted in
recovery of podocyte ultrastructure (Fig. 6) and a reduction of pro-
teinuria (Ortmann et al., 2004). The effects of ERA treatment were in-
dependent of renal or systemic hemodynamics or blood pressure
(Ortmann et al., 2004). This suggested direct structural rather than
pressure-dependent effects mediated by ET-1, compatible with its
growth-promoting, pro-inﬂammatory functions (Fig. 3) (Barton,
2008). Pressure-independent regression of glomerulosclerosis
using ERAs has also been observed in a model of decreased NO bioac-
tivity (Placier et al., 2006), a condition also resembling physiological
aging (Brandes et al., 2005; Tschudi et al., 1996). Deﬁciency of the
klotho gene is associated with accelerated aging (Kuro-o et al.,
1997) and its over-expression extends lifespan (Kurosu et al.,
2005). Interestingly, age-related kidney injury is associated with
reduced klotho expression (Zuo et al., 2011), and gene therapy to
increase klotho concentrations has been shown to prevent the upreg-
ulation of ET-1 and the kidney disease associated with it (Wang and
Sun, 2014), further reinforcing a role of ET-1 in aging of the kidney.
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Untreated ERA for 4 weeks
Fig. 6. Effects of endothelin receptor antagonist on aging-dependent organ injury in the kidney. In humans and rodents, aging is associated with spontaneous development of focal-
segmental glomerulosclerosis (FSGS), shown in are histological (A, B) or electron microscopic (C–F) sections of kidneys of aged rats with established FSGS, either untreated (left) or
after 4 weeks of treatmentwith anETA-selective endothelin receptor antagonist (ERA), darusentan (right panels). Comparedwith untreated rats, ERA treatment resulted inpartial reversal
of renal aging. A:, In untreated rats, moderate mesangial matrix expansion and hypertrophy of podocytes with enlarged nuclei, prominent nucleoles (arrow), and many intra-
cytoplasmatic vesicles (open arrow) were detected, compatible with injury and activation of podocytes. B: Following ERA treatment, glomerular injury was reduced, mesangial matrix
expansion and podocyte hypertrophy and activation were milder compatible indicative of regression of glomerular aging (bar, 50 μm). Panels C–F show representative transmission
electron micrographs of podocytes and glomerular basement membranes. C: Without treatment, glomerular basement membrane hypertrophy and injury and detachment of podocytes
are visible. E: High-powermicrograph indicating thickening of glomerular capillary basementmembranewith podocyte detachment. Injury of podocytes is characterized by hypertrophy,
inclusion of cytoplasmatic absorption droplets due to vacuolar degeneration, and diffuse effacement of foot processes. D: ERA treatment for four weeks was associated with partial,
improved attachment of the podocyte to the basement membrane and complete normalization of glomerular capillary hypertrophy. F: High-power micrograph showing partial reversal
of podocyte aging after ERA treatment. Treatment was associatedwith a reduction of podocyte injury and complete disappearance of intra-cytoplasmatic vesicles which is also evident in
panel B. Reproduced from Ortmann J, Amann K, Brandes RP, Kretzler M, Münter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M. Role of podocytes for the reversal of
glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44: 974–981, with permission of the publisher.
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Considering that angiotensin II, another MMM, also becomes
activated with aging (Baylis and Corman, 1998; Benigni et al., 2009;
Ma et al., 2000), and that angiotensin II represents an important induc-
tor of ET-1 both in vitro and in vivo (Barton et al., 1997b; d'Uscio et al.,1998; Moreau et al., 2000), the regression of aging-induced renal injury
observed with ACEi or ARB treatment (Adamczak et al., 2004, 2003; Ma
et al., 2000) or the improvement of age dependent endothelium-
dependent vascular dysfunction in rodents (Mukai et al., 2002) and
humans (Rajagopalan et al., 2002) may at least in part underlie inhibi-
tion of the production of endothelin. Other endothelin-modifying
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1998). Finally, drugs targeting ET receptors may also have desir-
able off-target effects, such as ACE inhibitor function, which indi-
rectly would also reduce renal ET-1 production by inhibiting
angiotensin II formation (Barton et al., 2000a). Treatment with
the above drugs is likely to affect the production and activity of en-
dothelial MMMs at multiple levels. Preclinical and clinical studies
(including those employing ERAs) have reported regression of
pathological abnormalities achieved by blocking or interfering
with receptor for angiotensin (Adamczak et al., 2004, 2003;
Benigni et al., 2009; Ma et al., 2000) or endothelin (Fig. 6)
(Barton, 2008; Boffa et al., 2001; Ortmann et al., 2004; Placier
et al., 2006). These studies support at least a partial causal role of
the ET-1 peptide both in disease and in the physiological aging pro-
cess. This is important to keep in mind with regard to primary and
secondary disease prevention as well as healthy aging that I will
address with in the following paragraph. Finally, costs related to
pharmacological interventions are enormous, reaching billions an-
nually (Prasad and Vandross, 2012), a ﬁgure that is expected to in-
crease even further in the future.*XLGHOLQHIRU+HDOWKDQG+HDOWK\$JLQJ
“Ask not what your body can do for you;
ask what you can do for your body!
Ask not what your physician will do for you
but what, together, both can do for better health.”
Fig. 7. A guideline for health and healthy aging proposed by the author to raise awareness
about the need of active participation in disease prevention. The text was adapted from a
quote by former U.S. President John F. Kennedy taken from his 1961 inauguration speech.
The guideline allows physicians, patients, parents, educators, and health professionals to
recognize the great potential of active participation inhealth preservation anddisease pre-
vention and facilitates its communication.Endothelial therapy: physical activity, nitric oxide, and beyond
Since only patients diagnosed with a disease are eligible to receive a
speciﬁc drug treatment, additional therapeutic and particularly preven-
tive measures are required. One of the most underused, yet highly
effective ones is regular exercise (Barton, 2012, 2013d; Franklin and
Pierce, 2014; Wienbergen and Hambrecht, 2013). Data accumulated
over the past two decades suggests that interventions such as simple
as physical activity have effects that are comparable to those of drug
treatments (Wienbergen and Hambrecht, 2013). Regular physical exer-
cise is one of the most powerful means to increase the bioactivity of ni-
tric oxide (NO), which is an important inhibitor of ET-1 production and
activity. Exercise has anti-diabetic, anti-hypertensive (reviewed in
Barton, 2013d), and anti-inﬂammatory effects (Caulin-Glaser et al.,
2005; Gielen et al., 2005), and increases the protective properties of
HDL cholesterol (Adams et al., 2013). Given the apparent disease-
promoting activity of ET-1 via activation of its ETA-receptors (Barton,
2008) (Fig. 5), it is conceivable that any efforts directed at inhibiting
activity or reducing the production of any endothelium-derived,
disease-promoting factor (including ET-1) are likely to result in
improvement in disease outcome. I previously coined this approach
“endothelial therapy”, which incorporates preventive measures, physi-
cal exercise, and if required drugs targeting endothelial factors or
MMMs and aims at restoring normal endothelial cell homeostasis
(Barton, 2013d; Barton and Haudenschild, 2001; Traupe et al., 2003).
Since introducing the concept of endothelial therapy, colleagues have
followed now suggesting that physicians should “prescribe” physical ac-
tivity as medicine (Brooks and Ferro, 2012; Exercise Medicine Initiative,
2014; Hellenius and Sundberg, 2011; Nunan et al., 2013). Physical exer-
cise, by increasing the release of endothelial NO and by reducing the
bioactivity of ET-1, may thus directly affect and delay the aging pro-
cess (Barton, 2013d, Franklin and Pierce, 2014; Liu et al., 2014). In-
deed, endurance training reduces circulating levels of ET-1 in
elderly women (Maeda et al., 2003), blunts the ET-1-mediated in-
crease in vascular tone in elderly subjects (Thijssen et al., 2007;
Van Guilder et al., 2007), and prevents the physiological increase in
blood pressure seen with aging (Franklin and Pierce, 2014; Liu et
al., 2014). Finally, physical activity in elderly individuals has pro-
found effects on the immune system, particularly senescent T cells,
and has been found to interfere with the general inﬂammatory acti-
vation seen with aging (Kohut and Senchina, 2004; Senchina and
Kohut, 2007; Simpson et al., 2010; Spielmann et al., 2011). Thus,
aging represents one of the key targets for applying endothelial ther-
apy and preventive medicine.Telomere regulation: nitric oxide, endothelin, and exercise
Aging is characterized by shortening of telomeres, structures in
chromosomes that are involved in replication and stability of DNA
molecules (Fuster et al., 2007). Telomere shortening is one of the key
processes involved in cellular senescence (El Assar et al., 2012). Increas-
ing the bioactivity of NO – for example through regular exercise – leads
to activation telomerase (Hayashi et al., 2008; Vasa et al., 2000).
Conversely, bioactivity and production of NO itself require the activity
of the TERT-subunit of telomerase (Matsushita et al., 2001), an enzyme
implicated in the protection from cancer and aging (Fuster et al., 2007).
The interaction between vascular function and telomerase is further
supported by data from Rodrigues-Puyol and colleagues who found
that deletion of telomerase results in arterial hypertension, as well as
upregulating ECE-1 overexpression in a ROS/NADPH-oxidase-depen-
dent manner (Perez-Rivero et al, 2006). Along the same lines, Laufs,
Werner and colleagues in several experimental studies found that
regular physical exercise improves telomere function/expression of
telomerase-regulating proteins, compatible with a reversing effect of
exercise on vascular aging (Werner et al., 2009, 2008).Disease prevention and healthy aging
Realizing the potential of applying preventive medicine
Disease prevention is the ﬁrst step towards healthy aging (Barton,
2013d). Due to their multifactorial nature no speciﬁc treatment for the
aforementioned, chronic “degenerative” diseases is available. This,
once more, reinforces the importance of early intervention to achieve
primary disease prevention (Barton, 2012). Any disease prevention –
be it primary or secondary – requires awareness. Awareness depends
on obtaining sufﬁcient information, understanding and recognizing its
importance (Barton, 2012, 2013a). Most chronic diseases show a
much higher prevalence in the elderly than in the normal population
(Fig. 2) and are associated with endothelin activation and an inﬂamma-
tory component; thus, aging represents a complex, disease-promoting
network of cellular changes and factors – including endothelial factors
(Barton, 2010) – that ultimately increases the risk of disease and
death (Harman, 1991). It is therefore important to recognize and
apply preventive modalities such as physical exercise and endothelial
therapy (Barton, 2013d) - among others - that allow healthy aging as
long as possible. Human life span is genetically ﬁnite, as suggested
from a recent study and thus unlikely to be ever expanded (Holstege
et al., 2014) and appears to be limited to around 130 years (Payne,
2014).
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In industrialized countries, the majority of deaths in the elderly
population is due to cardiovascular or cerebrovascular disease (particu-
larly in patients with arterial hypertension, diabetes or chronic kidney
disease) or to cancer (Mokdad et al., 2004). Thus, health preservation,
and if necessary, secondary disease prevention are key for both patients
and physicians. Disease prevention must start early in families and
schools (Barton, 2012), to form a basis for lifelong health which at a
later point will also allow healthy aging. To increase awareness about
the need for active participation I have recently proposed a guideline
(Fig. 7) (Barton, 2013d). When put into practice, this guideline may
help individuals to realize the beneﬁt of receiving better health, i.e.
more healthy years as a “return of investment” in the course of their
life, or that of their children (Barton, 2013d). Importantly, this beneﬁt
will extend also to individuals who wish to maintain their health, as
well as to patients with the same intention who are diagnosed with a
chronic disease (Barton, 2013d). This guidelinemay also be used by par-
ents, grandparents, school teachers, educators, colleagues at work, etc.
to help increase health awareness and increase motivation to take
action.
With regard to keeping a physically active lifestyle it is important to
remember that – no matter at what age (Millar, 1984) – actively
contributing to preventionwill positively reﬂect on families, their social
environment, and society in general. Moreover, serving as role models
for healthy living is likely to improve overall health of societies in the
long term (Fig. 7) (Barton, 2012, 2013d). Thus, for senior citizens,
their families, and their physicians the goal should be allow “healthy
aging” as much as possible (Barton, 2005b; Franklin and Pierce, 2014).
“We must aim to add life to years not years to life” (Drewnowski and
Evans, 2001; Millar, 1984) has been a key motto of healthy aging,
which can also be described as “extending functional life span”
(Harman, 1996) or “successful aging” (Newman et al., 2003). A decade
ago I discussed the prospects of healthy aging (Barton, 2005b), also ad-
dressing the importance of providing and sharing information about ac-
tively participating in disease prevention and successful aging, a
statement that I would like to reiterate here:
“Despite the availability of simple interventions such as improving
cardiovascular ﬁtness – a powerful tool to reduce cardiovascular
mortality, improve plasticity in the aging human brain, and reduce
immunosenescence and even oxidative stress – , or simply cutting down
on food intake and maintaining a healthy body weight to delay aging-
related changes, the potential of many of these measures is far from
being fully recognized and is much underused. The goal of our efforts
should not be to enable humans to live as long as possible but rather
to have a life for as long as possible. Therefore, providing information
to allow early prevention of disease will be the ﬁrst step to successful
aging.”Successful and healthy aging: disease prevention must start in youth
Aging begins with the day that we are born. Alarmingly, the number
children diagnosedwith obesity and/or diabetes –who carry a life-long
health risk to develop chronic diseases (Barton, 2012; Barton and Furrer,
2003; Virdis et al., 2009) – continues to increase. Exercise, no matter
how old you are, has been shown to be a most suitable tool (Chen and
Millar, 1999; Franklin and Pierce, 2014; Liu et al., 2014) and involves
hardly any costs (Barton, 2012). Thus, another goal is to prevent today's
children from becoming tomorrow's patients (Barton, 2013a). Improv-
ing ormaintaining healthy functions of endothelial cells and their medi-
ators has been shown to prolong life (Gielen et al., 2008; Green et al.,
2008; Schächinger et al., 2000). Fortunately, the World Health Organi-
zation, local governments, and medical societies have recognized the
importance and the preventive potential of physical activity and areactively promoting its use (Exercise Medicine Initiative, 2014; Haskell
et al., 2007; Swedish National Institute of Public Health, 2010;
Thompson et al., 2003; Zoghbi et al., 2014), which has led to different
recommendations by theWorld Health Organization for all age groups,
including children and the elderly (WHO Recommendations, 2010).
Finally, aside from its roles in the aging process and chronic diseases,
we must remember that ET-1 – produced at physiological concentra-
tions and under healthy conditions – is required for maintaining a
multitude of cellular and physiological functions (Barton and
Yanagisawa, 2008; Kohan et al., 2011a, 2011b; Schneider et al., 2007).
After all, ET-1 (and its ETA receptor) are crucially involved in the ﬁrst
steps of life, namely embryogenesis (Kurihara et al., 1995, 1994)— a de-
velopment phase already involvingmechanism of senescence (Campisi,
2014; Muñoz-Espín et al., 2013; Storer et al., 2013); thus, as previously
stated, “there would be no life without endothelin” (reviewed in
Moeller-Gorman, 2010) — and no aging to begin with.
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